Keisuke Monji
Overview
Explore the profile of Keisuke Monji including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
94
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Furukawa J, Kato T, Yamasaki T, Monji K, Tanaka T, Tsuchiya N, et al.
Int J Clin Oncol
. 2025 Feb;
PMID: 39934514
Background: Avelumab + axitinib was approved for the treatment of advanced renal cell carcinoma (aRCC) in Japan in December 2019. We report long-term real-world subgroup analyses with first-line avelumab + ...
2.
Fujita K, Matsushita Y, Toyoda S, Kojima T, Yamashita S, Taniguchi H, et al.
World J Urol
. 2024 Sep;
42(1):536.
PMID: 39325218
Purpose: Metastatic non-clear cell renal cell carcinoma (nccRCC) is a heterogeneous disease with a poor prognosis and is treated with immunotherapy (IO)-based combinations according to the clear cell renal cell...
3.
Tomida R, Takahashi M, Matsushita Y, Kojima T, Yamana K, Kandori S, et al.
Clin Genitourin Cancer
. 2024 May;
22(3):102094.
PMID: 38714434
Background: To date, no studies have compared the treatment outcomes of second-line therapies in patients with metastatic clear cell renal cell carcinoma (ccRCC). This study retrospectively evaluated the efficacy of...
4.
Blas L, Monji K, Mutaguchi J, Kobayashi S, Goto S, Matsumoto T, et al.
Int J Clin Oncol
. 2023 Dec;
29(8):1105-1114.
PMID: 38108981
In the last decade, the standard treatment for advanced renal cell carcinoma (RCC) has evolved, mainly driven by the development and approval of immune checkpoint inhibitors (ICIs). Currently, ICI monotherapy...
5.
Kashiwagi E, Shiota M, Inokuchi J, Tsukahara S, Imada K, Monji K, et al.
Anticancer Res
. 2023 Aug;
43(9):4249-4254.
PMID: 37648320
Background/aim: Testosterone is essential for prostate cancer development and growth. This study aimed to investigate the relationship between testosterone in seminal vesicles and prostate cancer incidence and its malignant phenotype....
6.
Shiota M, Tsukahara S, Ueda S, Mutaguchi J, Goto S, Kobayashi S, et al.
J Robot Surg
. 2023 Aug;
17(6):2721-2728.
PMID: 37634216
The novel technique of lateral pelvic fascia preservation (LPFP) in robot-assisted radical prostatectomy (RARP) has been reported to improve urinary continence recovery. We aimed to investigate surgical and oncological outcomes...
7.
Ohba K, Monji K, Osawa T, Yamana K, Yasuda Y, Tanaka H, et al.
Int J Urol
. 2023 Jul;
30(11):977-984.
PMID: 37434386
Objectives: Current prognostic models for metastatic renal cell carcinoma (mRCC) are likely inaccurate due to recent treatment advances and improved survival outcomes. The JEWEL study used a data set from...
8.
Blas L, Shiota M, Tsukahara S, Goto S, Kinoshita F, Matsumoto T, et al.
Int J Urol
. 2023 Apr;
30(7):600-604.
PMID: 37078488
Objective: The precise diagnosis of prostate cancer (PC) is crucial to avoid underdiagnosis, overdiagnosis, and overtreatment. We aimed to compare clinically significant PC (csPC) detection between MRI/ultrasound fusion-targeted prostate (TBx)...
9.
Blas L, Shiota M, Nagakawa S, Tsukahara S, Matsumoto T, Lee K, et al.
Asian J Urol
. 2023 Feb;
10(1):81-88.
PMID: 36721693
Objective: There are many models to predict extracapsular extension (ECE) in patients with prostate cancer. We aimed to externally validate several models in a Japanese cohort. Methods: We included patients...
10.
Blas L, Shiota M, Takamatsu D, Kinoshita F, Matsumoto T, Lee K, et al.
World J Urol
. 2022 Dec;
41(1):43-50.
PMID: 36527468
Purpose: Conditional survival represents the probability of subsequent survival given that patients have already survived a certain length of time. Several models predict biochemical recurrence (BCR) after radical prostatectomy. However,...